Financial toxicity in patients with gynecologic malignancies: a cross sectional study.
Cervix Cancer
Financial Stress
Ovarian Cancer
Uterine Cancer
Vagina Cancer
Vulva Cancer
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
21
04
2021
revised:
17
06
2021
accepted:
19
07
2021
pubmed:
26
8
2021
medline:
15
12
2021
entrez:
25
8
2021
Statut:
ppublish
Résumé
To evaluate financial toxicity and assess its risk factors among patients with gynecologic cancers. This is a cross sectional study that included 2 survey tools, as well as patient demographics, disease characteristics, and treatment regimen. Financial toxicity is measured by validated Comprehensive Score for Financial Toxicity (COST) tool. Participants were also asked to complete a 55-question-survey on attitudes and perspectives surrounding cost of care. Descriptive statistics was used to report patient demographics. Spearman's rank correlation was calculated to assess the relation between financial toxicity and patient/disease related variables. Graphpad Prism Software Version 8.0 was used for analyses. A total of 50 patients with various gynecologic malignancies were enrolled. Median COST score was 20.5 (range, 1-33). Sixty-five percent of the patients reported being in debt due to their cancer care and 4% filed bankruptcy. Correlation analysis showed that COST score was correlated with age (r=-0.3, p=0.028), malignancy type (r=0.3, p=0.039) and income (r=0.3, p=0.047). Ovarian cancer patients had significantly less financial toxicity (median COST score=23) when compared to patients with other gynecologic malignancies (median COST score=17, p=0.043). When scores were dichotomized into low (score ≥22) and high toxicity (score <22), 58% (29/50) of the patients were noted to have high financial toxicity. Enrollment to a clinical trial did not significantly alleviate financial burden. Financial toxicity is a significant burden even among highly insured gynecologic oncology patients. Age, malignancy type and income were correlated with high financial burden.
Identifiants
pubmed: 34431257
pii: 32.e87
doi: 10.3802/jgo.2021.32.e87
pmc: PMC8550931
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e87Subventions
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176067
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2021. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No funding was received to assist with the preparation of this manuscript.
Références
Am J Obstet Gynecol. 2019 Aug;221(2):136.e1-136.e9
pubmed: 30965052
J Natl Cancer Inst. 2016 Oct 20;109(2):
pubmed: 27754926
Lancet Haematol. 2015 Oct;2(10):e408-16
pubmed: 26686042
Lancet. 2017 Oct 7;390(10103):1654-1663
pubmed: 28756902
Health Aff (Millwood). 2014 Oct;33(10):1721-7
pubmed: 25288415
Cancer. 2017 Feb 1;123(3):476-484
pubmed: 27716900
Cancer. 2014 Oct 15;120(20):3245-53
pubmed: 24954526
J Clin Oncol. 2012 May 10;30(14):1608-14
pubmed: 22412136
J Oncol Pract. 2014 Sep;10(5):332-8
pubmed: 24865220
Lancet Oncol. 2019 May;20(5):711-718
pubmed: 30922731
J Clin Oncol. 2017 Aug 1;35(22):2482-2489
pubmed: 28471711
Gynecol Oncol. 2020 Feb;156(2):271-277
pubmed: 31771866
Cancer. 2015 Dec 15;121(24):4425-32
pubmed: 26501494
Oncology (Williston Park). 2013 Feb;27(2):80-1, 149
pubmed: 23530397
Gynecol Oncol. 2019 Jul;154(1):8-12
pubmed: 31053404
Cancer. 2019 May 15;125(10):1737-1747
pubmed: 30663039
J Clin Oncol. 2016 Jan 20;34(3):259-67
pubmed: 26644532
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1304-1312
pubmed: 32522832
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Oncol. 2018 Feb 1;36(4):319-325
pubmed: 29016226